All News

RN.podcast.resized.jpg

RheumNow Podcast – Late Breaking Abstract Wrap-Up (6.21.19)

d Jack Cush, MD

Dr. Jack Cush reviews the week’s news and wrap up from EULAR19.

Read Article
EULAR19.podcast.jpg

EULAR 2019 - Podcast #1

d Jack Cush, MD

This EULAR 2019 Podcast is a compilation of audio clips from EULAR 2019 in Madrid.

 

Click HERE to listen.

 

Read Article
knee.surg2_.jpg (keep)

No Difference Among Biologics in Arthroplasty Infectious Risk

d Jack Cush, MD

A large administrative claims analysis of rheumatoid arthritis (RA) patients undergoing arthroplasty has shown no difference among biologics with regard to the risk of infections, but corticosteroid use was associated with a dose dependent risk of infection. 

Read Article
BP.jpg

Allopurinol Fails to Curtail Hypertension

d Jack Cush, MD

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.



Hypertension is one of the many comorbidities that plagues gout patients.

Read Article
guidelines.jpg (keep)

ACP Guidelines on Developing Evidence Based Clinical Guidelines

d Jack Cush, MD

Recommendations for the screening, diagnosis, and treatment of various diseases often differ by organization, making it difficult to know which ones to follow.

Read Article
Lymetick.jpg

Borrelia burgdorferi Peptidoglycan Shedding Drives Lyme Arthritis

d Jack Cush, MD

Research published in PNAS has shown that long after active Lyme infection in the joint, a peptidoglycan (PG) of the the spirochete Borrelia burgdorferi can be found in the joints of those with late-stage Lyme disease.



 

Read Article
Xeljanz4.jpg

Is Methotrexate Necessary with Tofacitinib?

d RheumNow

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Read Article
The RheumNow Podcast is up! This time its a Late Breaking Abstract Wrap-Up. Watch it here>> https://t.co/ZoVE5gSdG9 or Podcast listen on iTunes, in your car on Apple Car play or on SoundCloud here>> https://t.co/6AwVH1Zjoy 😲

Links:

Dr. John Cush RheumNow ( View Tweet)

Give me your take for my next ED in @HealioRheum on DTC-Direct to-consumer adverstising of Drugs/Biologics (as seen on national TV news : I am reasonably in favor of ( @psufka @DrBhana @AngusWorthing @RheumNow @autoimmunitymd @AutoimmuneList @SjogrensOrg )

Leonard Calabrese LCalabreseDO ( View Tweet)

CDC reports a 3-10mos shortage of Aplisol, a PPD product. Another PPD product, Tubersol is available for skin testing. CDC recs to use IGRA blood tests for TST & prioritize TSTs. Switching from PPD to IGRA may result in conversions requiring interpretation https://t.co/eJGOHVCbkO

Links:

Dr. John Cush RheumNow ( View Tweet)

"Clinicians should assess test results based on the person's likelihood of infection and risk for progression to TB disease, if infected," according to the CDC. MMWR. 2019;68:552-553. https://t.co/eJGOHVCbkO

Links:

Dr. John Cush RheumNow ( View Tweet)

Hear nine experts talk about biosimilars in “Therapeutic Update: Biosimilars in Rheumatology”, a video series brought to viewers by Sandoz. Now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars https://t.co/EXf19NB6g8

Links:

Dr. John Cush RheumNow ( View Tweet)
Lupus Research Alliance has awarded 2019 Lupus Insight Prize to Ignacio Sanz, MD, (Chief of Rheumatology, Emory Univ School of Medicine) for discovering that molecular mechanisms that underpin B cell activation pathway promoting lupus symptoms. https://t.co/RKFprO2wwj

Links:

Dr. John Cush RheumNow ( View Tweet)

FORWARD, a National Databank study, looked at malignancies & infections in RA pts starting abatacept, other biologicsor DMARDs. No difference in cancer risks, but ABA had lower risk hospitalized infx (HR 0.37) & lower infusion/injx rxn than other biologics https://t.co/9GonhVTK3Z

Links:

Dr. John Cush RheumNow ( View Tweet)

Methotrexate assoc. lymphoproliferative disorders (LPDs), is a rare disorder that resolves w/ MTX withdrawal (in 3-10mos). Most common path was diffuse large B-cell lymphoma and 45-77% had Epstein-Barr virus encoded RNA positivity. https://t.co/xF8YLiI2lc

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULAR2019 Emapalumab - a monoclonal Ab against IFNγ - was shown to be effective in 6 systemic JIA patients with macrophage activation syndrome. Rx led to rapid neutralization of IFNγ, normalization of CXCL9, & decreased T cell activation. OP0204 https://t.co/5K58IUNdCV
Dr. John Cush RheumNow ( View Tweet)
A survey of 900 Danish rheumatic dz pts shows that 1 in 10 with pain have considered suicide in the last 4 weeks and that this was strongly influenced by poor quality sleep. #EULAR2019 OP0347 https://t.co/hfIWXEC4Xo

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULAR2019 Come hear the latest on gout! Room N103 16:15-17:45 today. Risk:Exciting new genetics, occupational hazard, diet and inflammation. Treatment: New effectiveness measure, DECT to diagnose, flare prophylaxis, treat to target to prevent increased mortality @rheumnow #gout

Gout Study Group GoutGroup ( View Tweet)

#Gout and #genetics at #EULAR2019. New data on genes linked to sUA regulation and leading-edge genetics on conversion from #hyperuricemia to gout were shown in talks OP47 and OP48 @Rheumnow https://t.co/d6pikodu6K
Gout Study Group GoutGroup ( View Tweet)

A study examined whether EGCG suppresses the activation of the NLRP3 inflammasome, thereby effectively preventing gouty #inflammation. It was found that EGCG reduces inflammation in mouse foot tissue making it a promising treatment option for #gout https://t.co/X9O2mbJx6A https://t.co/wgUYz0BmeY

Links:

Gout Study Group GoutGroup ( View Tweet)
×